- Home
- GCGR vs ZVRA Comparison
GCGR vs ZVRA Comparison
Compare GCGR & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GCGR | ZVRA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 469.3M | 562.2M |
| IPO Year | 2026 | 2015 |
Fundamental Metrics
Financial Performance| Metric | GCGR | ZVRA |
|---|---|---|
| Price | $10.10 | $11.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 25.8K | ★ 1.4M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | N/A | ★ 0.74 |
| Revenue | N/A | ★ $106,470,000.00 |
| Revenue This Year | N/A | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | ★ N/A | $15.11 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $10.05 | $7.16 |
| 52 Week High | $10.20 | $15.04 |
Technical Indicators
Market Signals| Indicator | GCGR | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 48.68 | 48.18 |
| Support Level | $10.09 | $8.20 |
| Resistance Level | N/A | $12.19 |
| Average True Range (ATR) | 0.01 | 0.46 |
| MACD | -0.00 | 0.15 |
| Stochastic Oscillator | 11.11 | 64.43 |
Price Performance
Historical ComparisonAbout GCGR General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares
General Catalyst Global Resilience Merger Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.